» Articles » PMID: 2242528

Adaptation to Ischemia During Percutaneous Transluminal Coronary Angioplasty. Clinical, Hemodynamic, and Metabolic Features

Overview
Journal Circulation
Date 1990 Dec 1
PMID 2242528
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical, electrocardiographic, and coronary hemodynamic responses to sequential 90-second occlusions of the left anterior descending coronary artery in 12 patients undergoing elective percutaneous transluminal coronary angioplasty were examined. Transmyocardial lactate metabolism was examined in an additional group of seven patients with clinical and hemodynamic features similar to the first group. We noted that in comparison with the initial balloon occlusion the second occlusion was characterized by less subjective anginal discomfort, less ST segment shift (0.44 +/- 0.13 versus 0.21 +/- 0.07 mV, p = 0.01), and lower mean pulmonary artery pressure (25 +/- 1.0 versus 20 +/- 1.7 mm Hg, p = 0.005). In addition, for the same heart rate-blood pressure product, cardiac vein flow during the second inflation was significantly lower than that recorded during the first inflation (96 +/- 1.4 versus 83 +/- 2.4 ml/min, p = 0.005). Finally, there was significantly less myocardial lactate production during the second inflation (lactate extraction ratio: first inflation, -0.11 +/- 0.03; second inflation, -0.03 +/- 0.02; p = 0.04). We conclude that the lessened clinical, electrocardiographic, hemodynamic, and metabolic evidence of myocardial ischemia during the second of two periods of coronary artery occlusion during percutaneous transluminal coronary angioplasty supports the concept of adaptation to myocardial ischemia (ischemic preconditioning).

Citing Articles

Adenosine in Interventional Cardiology: Physiopathologic and Pharmacologic Effects in Coronary Artery Disease.

Marchi E, Muraca I, Berteotti M, Gori A, Valenti R, Marcucci R Int J Mol Sci. 2024; 25(11).

PMID: 38892037 PMC: 11172110. DOI: 10.3390/ijms25115852.


Myocardial Ischemia-Reperfusion Injury: Unraveling Pathophysiology, Clinical Manifestations, and Emerging Prevention Strategies.

Sagris M, Apostolos A, Theofilis P, Ktenopoulos N, Katsaros O, Tsalamandris S Biomedicines. 2024; 12(4).

PMID: 38672157 PMC: 11048318. DOI: 10.3390/biomedicines12040802.


Adenosine Receptor Subtypes and Cardioprotection.

Lee J, Wilcox K, Jacobson K, Dichter M, Liang B Drug Dev Res. 2024; 45(3-4):394-401.

PMID: 38234711 PMC: 10792443. DOI: 10.1002/(sici)1098-2299(199811/12)45:3/4<394::aid-ddr40>3.0.co;2-j.


P2X7 Receptors in Astrocytes: A Switch for Ischemic Tolerance.

Hirayama Y, Anzai N, Kinouchi H, Koizumi S Molecules. 2022; 27(12).

PMID: 35744780 PMC: 9228417. DOI: 10.3390/molecules27123655.


Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study.

Diaz-Munoz R, Valle-Caballero M, Sanchez-Gonzalez J, Pizarro G, Garcia-Rubira J, Escalera N Basic Res Cardiol. 2021; 116(1):45.

PMID: 34279726 DOI: 10.1007/s00395-021-00884-6.